| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 10/14/2004 | US20040204416 Pharmaceutical composition for the treatment of CNS and other disorders |
| 10/14/2004 | US20040204408 Piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity |
| 10/14/2004 | US20040204368 Oxadiazole derivative compounds and drugs containing these compounds as the active ingredient |
| 10/14/2004 | US20040204364 Peptides for activation and inhibition of deltaPKC |
| 10/14/2004 | US20040204355 alpha 7 receptor is the alpha -bungarotoxin sensitive receptor that influences the release of proinflammatory cytokines from macrophages |
| 10/14/2004 | US20040204345 Using recombinant zinc finger proteins; use in human therapeutic applications such as cancer therapy and altering plant phenotypes, including disease resistance, fruit ripening |
| 10/14/2004 | US20040203118 Polynucleotides and polypeptides of the IFNalpha-14 gene |
| 10/14/2004 | US20040203105 for drug screening emzyme inhibitors using genetically engineered animal models; for anticancer agents |
| 10/14/2004 | US20040203104 for drug screening enzyme inhibitors; genetic engineering; comprising subjecting the sample to a polymerase chain reaction, a northern hybridization assay or an in situ hybridization assay |
| 10/14/2004 | US20040203097 Kinases and phosphatases |
| 10/14/2004 | US20040203014 Neurotransmisson-associated proteins |
| 10/14/2004 | US20040202737 Process for obtention of decoctions of vitis labrusca and vitis vinifera skins |
| 10/14/2004 | US20040202736 Method of ameliorating side-effects of SERMs |
| 10/14/2004 | US20040202734 Method for preparing nicotianamine or nicotianamine-containing product |
| 10/14/2004 | US20040202731 Rosmarinic acid composition |
| 10/14/2004 | US20040202711 Delivery systems for periadventitial delivery for treatment of restenosis and anastomotic intimal hyperplasia |
| 10/14/2004 | US20040202656 Use of binding partners for 5-HT5 receptors for the treatment of neurodegenerative and neuropsychiatric disorders |
| 10/14/2004 | US20040202653 Peptide-based passive immunization therapy for treatment of atherosclerosis |
| 10/14/2004 | US20040202651 Uses of anti-insulin-like growth factor 1 receptor antibodies |
| 10/14/2004 | US20040202609 administering a cytotoxic compound of porphyrin complexed with a radioactive metal to a mammal; treating arteriosclerotic lesions; radioactive metal is cytotoxic to cells in and surrounding the plaque |
| 10/14/2004 | DE10315024A1 Wirkstoffkombination aus ω3-fettsäurehaltigen Ölen mit isoprenoidhaltigen Pflanzenextrakten und deren Verwendung Active ingredient combination of ω3-fatty acid-containing oils with isoprenoidhaltigen plant extracts and their use |
| 10/14/2004 | CA2521014A1 Combination drug therapy for treating hypertension |
| 10/14/2004 | CA2520372A1 Stq-peptides |
| 10/14/2004 | CA2519803A1 Use of erythropoietin in stroke recovery |
| 10/14/2004 | CA2518913A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof |
| 10/13/2004 | EP1466913A1 Benzoylecgonine, ecgonine and ecgonidine derivatives |
| 10/13/2004 | EP1466911A2 Preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| 10/13/2004 | EP1466901A1 Serotonine reuptake inhibitor |
| 10/13/2004 | EP1466891A1 Carboxylic acid derivative |
| 10/13/2004 | EP1466888A1 Calcium receptor-active arylalkyl amines |
| 10/13/2004 | EP1466649A1 Pharmaceutical composition containing artificial oxygen carrier |
| 10/13/2004 | EP1466624A1 Drug for regenerating tissue and vessel and method therefor |
| 10/13/2004 | EP1466622A1 Medicinal agent and method for curing diseases accompanied with vascular dystonia |
| 10/13/2004 | EP1466621A1 Compositions for improving lipid metabolism |
| 10/13/2004 | EP1466615A1 Pharmaceutical composition |
| 10/13/2004 | EP1466605A2 Calcium channel blockers |
| 10/13/2004 | EP1466604A1 Isoquinoline derivatives, process for their preparation and use thereof in the treatment of melatoninergic system problems |
| 10/13/2004 | EP1466602A1 Organ fibrosis inhibitors |
| 10/13/2004 | EP1466597A1 Use of dha esters to control or prevent cardiovascular diseases |
| 10/13/2004 | EP1466175A2 SPHKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 10/13/2004 | EP1465998A2 Single nucleotide polymorphisms predicting cardiovascular disease and medication efficacy |
| 10/13/2004 | EP1465997A2 Use of biomolecular targets in the treatment and visualization of tumors |
| 10/13/2004 | EP1465983A2 Endothelial stem cells, populations, methods of isolation and use thereof |
| 10/13/2004 | EP1465916A2 Novel g proein-coupled receptor, gave7 |
| 10/13/2004 | EP1465900A1 Rho-kinase inhibitors |
| 10/13/2004 | EP1465895A2 4-oxo-4,7-dihydrofuro(2,3-b)pyridine-5-carboxamide antiviral agents |
| 10/13/2004 | EP1465891A2 Inhibitors of dipeptidyl peptidase iv |
| 10/13/2004 | EP1465889A1 Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| 10/13/2004 | EP1465888A2 Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues |
| 10/13/2004 | EP1465880A1 5-sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine |
| 10/13/2004 | EP1465875A1 Novel alkansulfonamides as endothelin antagonists |
| 10/13/2004 | EP1465871A1 Pyrazole derivatives for use in diseases associated with the 5-ht2c receptor |
| 10/13/2004 | EP1465870A2 Substituted 4-phenyltetrahydroisoquinolinium salts, method for production and use thereof as a medicament and medicaments comprising the same |
| 10/13/2004 | EP1465869A1 Modulators of lxr |
| 10/13/2004 | EP1465866A2 Protease inhibitors of the coagulation cascade isolated from dysidea sponges |
| 10/13/2004 | EP1465864A1 Inhibitors of factor xa and other serine proteases involved in the coagulation cascade |
| 10/13/2004 | EP1465863A1 Potassium channel modulators |
| 10/13/2004 | EP1465858A2 Pheny(alkyl)carboxylic acid derivatives and dionic phenylalkylheterocyclic derivatives and their use as medicines with serum glucose and/or serum lipid lowering activity |
| 10/13/2004 | EP1465854A2 Chalcone derivatives and their use to treat diseases |
| 10/13/2004 | EP1465852A1 Synthesis of combretastatin a-2 prodrugs |
| 10/13/2004 | EP1465653A1 Therapeutic application of g-csf, gm-csf and scf |
| 10/13/2004 | EP1465652A2 Povidone-containing carriers for polypeptide growth factors |
| 10/13/2004 | EP1465650A2 Sk-3 potassium channels and the treatment of sexual dysfunctions and/or vascular disorders |
| 10/13/2004 | EP1465649A2 Methods and compositions for derepression of iap-inhibited caspase |
| 10/13/2004 | EP1465635A2 Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole analogues |
| 10/13/2004 | EP1465631A2 Pyrimidine a2b selective antagonist compounds, their synthesis and use |
| 10/13/2004 | EP1465630A1 Cyclic urea derivatives with 5-ht2c receptor activity |
| 10/13/2004 | EP1465627A1 DOSING REGIMEN FOR PPAR−GAMMA ACTIVATORS |
| 10/13/2004 | EP1465626A2 Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses |
| 10/13/2004 | EP1465624A1 Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof |
| 10/13/2004 | EP1465623A1 Urea derivatives |
| 10/13/2004 | EP1465620A2 Novel composition of carvedilol |
| 10/13/2004 | EP1465619A1 Suppression of cartilage degradation via the estrogen receptor |
| 10/13/2004 | EP1465616A1 Treatment of statin side effects using uridine derivatives |
| 10/13/2004 | EP1465613A2 Combination of mtp inhibitors or apob secretion inhibitors with fibrates for use as drugs |
| 10/13/2004 | EP1465605A1 Pravastatin pharmaceutical formulations and methods of their use |
| 10/13/2004 | EP1465596A1 Polymeric gel system for the controlled delivery of codrugs |
| 10/13/2004 | EP1465592A2 Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules |
| 10/13/2004 | EP1465521A2 System and method for the pretreatment of the endplates of an intervertebral disc |
| 10/13/2004 | EP1430031A4 Kinetic resolution of a intermediate useful in the production of benazepril and analogues thereof |
| 10/13/2004 | EP1397137A4 Hydantion derivatives as inhibitors of matrix metalloproteinases |
| 10/13/2004 | EP1381615B1 ANTIDEPRESSANT INDOLETETRAHYDROPYRIDINE DERIVATIVES OF 2,3-DIHYDRO-7H- [1,4]DIOXINO[2,3-e]INDOLE |
| 10/13/2004 | EP1349547B1 Use of 5-aminolevulinic acid for the prophylaxis of restenosis |
| 10/13/2004 | EP1347987B1 Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| 10/13/2004 | EP1322309A4 High affinity small molecule c5a receptor modulators |
| 10/13/2004 | EP1286682A4 Methods and compositions for inhibiting immunoglobulin-mediated--reperfusion injury |
| 10/13/2004 | EP1280820B1 Anti-inflammatory compounds and uses thereof |
| 10/13/2004 | EP1261346A4 Modulation of cardiovascular injury |
| 10/13/2004 | EP1211253B1 Tricyclic dihydrobenzofuran derivatives, process for the preparation thereof and agents |
| 10/13/2004 | EP1207866B1 Delayed-action form of administration containing tramadol saccharinate |
| 10/13/2004 | EP1202965B1 Indole derivatives, processes for their preparation, pharmaceutical compositions containing them and their medicinal application |
| 10/13/2004 | EP1187831B1 Pyrrolidinyl, piperidinyl or homopiperidinyl substituted (benzodioxan, benzofuran or benzopyran) derivatives |
| 10/13/2004 | EP1177217B1 Amphiphile cyclodextrins, preparation and use thereof for solubilising organised systems and incorporating hydrophobic molecules |
| 10/13/2004 | EP1169038A4 Cyclic protein tyrosine kinase inhibitors |
| 10/13/2004 | EP1150954B1 Anti-imflammatory indole derivatives |
| 10/13/2004 | EP1131340B1 Hexapeptide with the stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation, differentiation and apoptosis |
| 10/13/2004 | EP1086086B1 Imidazolyl derivatives and their use as somatostatin receptor ligands |
| 10/13/2004 | EP1012291B1 Multiple site delivery of adenoviral vector for the induction of angiogenesis |
| 10/13/2004 | EP0934928B1 Cyclic amine derivatives |
| 10/13/2004 | CN1537167A Von willebrand factor (VWF)-cleaving enzyme |